Immunovant (IMVT) EV/EBIT: History & Chart

Immunovant, Inc.(IMVT)

Biotechnology · Durham, NY

$32.64-0.61 (-1.83%)

Delayed quote: Oct 6, 2026, 11:45 AM EDT

About Immunovant, Inc.

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

Durham, NY

315 employees

immunovant.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Eric Venker

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Immunovant, Inc. (IMVT)	$6.74B	N/A	N/A	N/A	N/A
Chemed Corporation (CHE)vs ›	$6.67B	19.94x	18.72x	22.18x	22.20x
Hims & Hers Health, Inc. (HIMS)vs ›	$6.59B	N/A	122.18x	157.05x	157.05x
Amneal Pharmaceuticals, Inc. (AMRX)vs ›	$6.56B	22.87x	21.09x	21.52x	21.53x
Lantheus Holdings, Inc. (LNTH)vs ›	$6.51B	21.64x	17.84x	25.59x	41.53x
Alkermes plc (ALKS)vs ›	$7.14B	69.94x	33.08x	18.53x	18.91x
Ionis Pharmaceuticals, Inc. (IONS)vs ›	$7.39B	N/A	860.73x	332.81x	269.88x
Ligand Pharmaceuticals Incorporated (LGND)vs ›	$6.02B	60.91x	129.47x	397.21x	199.00x
GRAIL Inc. (GRAL)vs ›	$6.00B	N/A	N/A	N/A	N/A
Iovance Biotherapeutics, Inc. (IOVA)vs ›	$5.95B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBIT RATIO

TTM

Immunovant, Inc. (IMVT)

$6.74B

N/A

Chemed Corporation (CHE)vs ›

$6.67B

19.94x

18.72x

22.18x